ARDX - Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia PA | Benzinga
WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced upcoming data presentations for tenapanor for hyperphosphatemia at the American Society of Nephrology (ASN) Kidney Week 2023 meeting to be held in Philadelphia, PA, November 1-5, 2023. XPHOZAH (tenapanor), discovered and developed by Ardelyx, is an investigational first-in-class phosphate absorption inhibitor.
Ardelyx will present four poster presentations highlighting data from two trials in patients with hyperphosphatemia on maintenance dialysis in the U.S. Additionally, the company's collaboration partner for tenapanor in Japan, Kyowa Kirin Co, Ltd. (Kyowa Kirin), will present key results from two Phase 3 studies of tenapanor in a similar patient population in Japan.
Information regarding ASN's Kidney Week, including copies of presentation abstracts, can be found at https://www.asn-online.org/education/kidneyweek.
Ardelyx Poster Presentations:
| Title: Optimal Initiation of Tenapanor Treatment Analyzed by Baseline Phosphate Binder Dose: A Sub-analysis of the OPTIMIZE Study |
| Authors: |
| Stuart Sprague, Jill Meyer, David Rosenbaum, Susan Edelstein, Yang Yang, Suling Zhao, David Spiegel |
| Poster Number: |
| TH-PO143 |
| Date/Time: |
| November 2, 2023 ... |